Evidence map›Paper›PMID 28521821›Full record

ArticleBreast cancer research : BCR2017

Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.

Nathaniel M Braman, Maryam Etesami, Prateek Prasanna, Christina Dubchuk, Hannah Gilmore, Pallavi Tiwari, Donna Plecha, Anant Madabhushi

Erratum issuedAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 397 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
397citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

397 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

337 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Nathaniel M BramanDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA. nathaniel.braman@case.edu.
Maryam EtesamiUniversity Hospitals Case Medical Center, Cleveland, OH, 44106, USA.
Prateek PrasannaDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.
Christina DubchukUniversity Hospitals Case Medical Center, Cleveland, OH, 44106, USA.
Hannah GilmoreUniversity Hospitals Case Medical Center, Cleveland, OH, 44106, USA.
Pallavi TiwariDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.
Donna PlechaUniversity Hospitals Case Medical Center, Cleveland, OH, 44106, USA.
Anant MadabhushiDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.

Funding

Interdisciplinary Biomedical Imaging Training ProgramT32EB007509 · NIBIB · CASE WESTERN RESERVE UNIVERSITY · PI DAVID Lynn WILSON, Xin Yu · 2007 to 2026
$5.6M
Computerized histologic image predictor of cancer outcomeR01CA202752 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI FELDMAN, MICHAEL D, GANESAN, SHRIDAR · 2016 to 2020
$3.1M
MR Fingerprinting and Computerized Decision Support for Prostate CancerR01CA208236 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GULANI, VIKAS, PONSKY, LEE EVAN · 2017 to 2022
$3.0M
Pathology Image Informatics Platform for visualization, analysis and managementU24CA199374 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GURCAN, METIN NAFI, MADABHUSHI, ANANT · 2015 to 2019
$2.9M
Comprehensive quantitative ultrafast 3D liver MRIR01DK098503 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI GULANI, VIKAS, SEIBERLICH, NICOLE · 2013 to 2017
$2.6M
Histologic image-based aggressiveness prediction in p16+ oropharyngeal carcinomaR21CA179327 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MADABHUSHI, ANANT · 2014 to 2015
$389k
Computerized morphologic-molecular predictor of progression in DCISR21CA195152 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI BADVE, SUNIL S., MADABHUSHI, ANANT · 2015 to 2016
$388k
BIOMEDICAL ENGINEERING RESEARCH FACILITIESC06RR012463 · NCRR · CASE WESTERN RESERVE UNIVERSITY · PI KUTINA, KENNETH L · 1997 to 1997
–
NCI NIH HHS R01 CA202752NCI NIH HHS R01 CA208236NCI NIH HHS R21 CA179327NCI NIH HHS R21 CA195152NCI NIH HHS U24 CA199374NCRR NIH HHS C06 RR012463NIBIB NIH HHS T32 EB007509NIDDK NIH HHS R01 DK098503
6 · The paper itself

Abstract

backgroundIn this study, we evaluated the ability of radiomic textural analysis of intratumoral and peritumoral regions on pretreatment breast cancer dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict pathological complete response (pCR) to neoadjuvant chemotherapy (NAC).

methodsA total of 117 patients who had received NAC were retrospectively analyzed. Within the intratumoral and peritumoral regions of T1-weighted contrast-enhanced MRI scans, a total of 99 radiomic textural features were computed at multiple phases. Feature selection was used to identify a set of top pCR-associated features from within a training set (n = 78), which were then used to train multiple machine learning classifiers to predict the likelihood of pCR for a given patient. Classifiers were then independently tested on 39 patients. Experiments were repeated separately among hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR

resultsAmong all patients, a combined intratumoral and peritumoral radiomic feature set yielded a maximum AUC of 0.78 ± 0.030 within the training set and 0.74 within the independent testing set using a diagonal linear discriminant analysis (DLDA) classifier. Receptor status-specific feature discovery and classification enabled improved prediction of pCR, yielding maximum AUCs of 0.83 ± 0.025 within the HR

conclusionsThrough a combined intratumoral and peritumoral radiomics approach, we could successfully predict pCR to NAC from pretreatment breast DCE-MRI, both with and without a priori knowledge of receptor status. Further, our findings suggest that the radiomic features most predictive of response vary across different receptor subtypes.

Indexed as

AdultAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreastContrast MediaErb-b2 Receptor Tyrosine KinasesFemaleHumansMachine LearningMagnetic Resonance ImagingMiddle AgedNeoadjuvant TherapyTriple Negative Breast NeoplasmsBiomarkers, TumorContrast MediaERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImagingMRINeoadjuvant chemotherapyPersonalized medicineRadiomicsTreatment response

Identifiers

PMID28521821
PMCPMC5437672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.